Compare · ACHV vs TNFA
ACHV vs TNFA
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and TNF Pharmaceuticals Inc. (TNFA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and TNFA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ACHV carries a market cap of $697.7M.
- ACHV has hit the wire 5 times in the past 4 weeks while TNFA has been quiet.
- ACHV has more recent analyst coverage (11 ratings vs 0 for TNFA).
- Company
- Achieve Life Sciences Inc.
- TNF Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $697.7M
- -
- 1M return
- -8.17%
- -
- 1Y return
- +54.90%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 0
- Recent ratings
- 11
- 0
ACHV
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV
- SEC Form 10-Q filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
Latest TNFA
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"
- TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing
- TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form D filed by TNF Pharmaceuticals Inc.
- TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits